Rosuva 10mg 10pcs

201

SKU: MERO-3 Category: Tag:

Description

DESCRIPTION ADDITIONAL INFORMATION REVIEWS PRODUCT ENQUIRY

PRESENTATION

RosuvaTM
5 Tablet: Each film coated tablet contains Rosuvastatin Calcium INN equivalent to 5 mg Rosuvastatin. RosuvaTM 10 Tablet: Each film coated tablet contains Rosuvastatin Calcium INN equivalent to 10 mg Rosuvastatin. RosuvaTM
20 Tablet: Each film coated tablet contains Rosuvastatin Calcium INN equivalent to 20 mg Rosuvastatin. PHARMACOLOGY
RosuvaTM
(Rosuvastatin) is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. Rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL. Second, Rosuvastatin inhibits hepatic synthesis of VLDL,which reducesthe total number of VLDL and LDL particles.
PHARMACOKINETICS:
Absorption
Peak plasma concentrations of Rosuvastatin were reached 3 to 5 hours following oral dosing. Both peak concentration (Cmax) and area under the plasma concentration-time curve (AUC) increased in approximate proportion to Rosuvastatin dose.
Distribution: 
Mean volume of distribution at steady-state of Rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin.
Metabolism
Rosuvastatin is not extensively metabolized. The major metabolite of Rosuvastatin is N-desmethyl rosuvastatin which has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of Rosuvastatin. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by Rosuvastatin.
Elimination
Following oral administration, Rosuvastatin and its metabolites are primarily excreted in the feces (90%).The elimination half-life (t
1/2) of Rosuvastatin is approximately 19 hours.
INDICATION AND USE:
Heterozygous Hypercholesterolemia (Familial and Nonfamilial)
Homozygous Hypercholesterolemia (Familial)
Mixed Dyslipidemia (Fredrickson Type Ila and lib)
DOSAGE AND ADMINISTRATION
Heterozygous Hypercholesterolemia (Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Type Ila and lib)
The usual recommended starting dose of Rosuvastatin is 10 mg once daily. Initiation of therapy with 5 mg once daily may be considered for patients requiring less aggressive LDL-C reductions or who have predisposing factors for myopathy. For patients with marked hypercholesterolemia (LDL-C> 190 mg/dL) and aggressive lipid targets, a 20 mg starting dose may be considered. The 40 mg dose of Rosuvastatin should be reserved for those patients who have not achieved goal LDL-C at 20 mg. After initiation and/or upon titration of Rosuvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.
Homozygous Hypercholesterolemia (Familial)
The recommended starting dose of Rosuvastatin is 20 mg once daily in patients with homozygous FH. The maximum recommended daily dose is 40 mg. Rosuvastatin should be used in these patients as an adjunct to other lipid-lowering treatments (eg., LDL apheresis) or if such treatments are unavailable. Patients with renal insufficiency. No modification of dosage is necessary for patients with mild to moderate renal insufficiency. For patients with severe renal impairment (CLcr <30 mL/min/1.73 m2) not on hemodialysis, dosing of Rosuvastatin should be started at 5 mg once daily and not to exceed 10 mg once daily. Dosage in Asian Patients.
Initiation of Rosuvastatin therapy with 5 mg once daily should be considered for Asian patients. Use with Cyclosporine, Lopinavir/Ritonavir or Atazanavir/Ritonavir In patients taking Cyclosporine, the dose of Rosuvastatin should be limited to 5 mg once daily. In patients taking Lopinavir and Ritonavir or Atazanavir and Ritonavir the dose of Rosuvastatin should be limited to 10 mg once daily.
CONTRAINDICATION:
Rosuvastatin is contraindicated in patients with a known hypersensitivity to any component of this product. Rosuvastatin is contraindicated in patients with active liver disease or with unexplained nersistent elevations of serum transaminases.

Additional information

Weight 0.35 kg
Dimensions 8 × 8 × 8 cm
Note

Product delivery duration may vary due to product availability in stock.

Reviews

There are no reviews yet.

Be the first to review “Rosuva 10mg 10pcs”

Your email address will not be published. Required fields are marked *